HDAC9 and cancer: MPT0E028, an orally administered N-hydroxyacrylamide-derived pan-HDAC inhibitor, showed a growth suppression effect in cultured NCI-60 human cancer cell lines, including leukemia, melanoma, lung, colon, breast, prostate, renal, and central nervous system cancers, in our previous study [15].